ฐานข้อมูลอันตรกิริยาระหว่างสมุนไพรกับยาแผนปัจจุบัน

Part Used : ใบ

Activity : CYP3A4 INHIBITION

Solvent/Active Compound : -

Type of experiment : human

Type of animal : -

Type of study : Open trial

N(Total) : 12 (M/F=6/6)

N(Treatment) : 12 (M/F=6/6)

Sex : Both sex

Age : 67+/-5.2 yrs.

Route : Oral administration

Dose/Conc.(herb) : 60 mg four times daily (standardized to 24% flavones glycoside and 6% terpene lactones)

Duration : 28 days

Type of interaction : Pharmacokinetics

Interaction with drug : Midazolam*/Versed/Dormicum

Dose/Conc.(drug) : 8 mg

Result : Negative

Remark :

Note : Twelve healthy volunteers were randomly assigned to receive each botanical supplement for 28 days followed by a 30-day washout period. Probe drug cocktails of midazolam, caffeine, chlorzoxazone and debrisoquine were administered before (days -1, 0) and at the end of supplementation (days 27, 28). Pre- and post-supplementation phenotypic ratios were determined for CYP3A4, CYP1A2, CYP2E1 and CYP2D6 using 1-hydroxymidazolam/midazolam serum ratios (1-hour), paraxanthine/caffeine serum ratios (6-hour), 6-hydroxychlorzoxazone/chlorzoxazone serum ratios (2-hour) and debrisoquine urinary recovery ratios (8-hour), respectively.

---